- Palabras clave > antibacterial resistance (ABR)
- Palabras clave > antibiotic resistance
- Palabras clave > antimicrobial resistance (AMR)
- Palabras clave > antimicrobial resistance surveillance
- Palabras clave > containing drug resistance - coalition-based approach
- Palabras clave > containment of antimicrobial resistance
- Palabras clave > health workers’ education and training on AMR
- Palabras clave > surveillance - antibiotic resistance and antibiotic use
- Palabras clave > training - health workers
- Palabras clave > workforce (requirements, staffing and training)
- Palabras clave > confinement antimicrobien
(2018; 28 pages)
The WHO Western Pacific Region has had much success in prevention of hepatitis, in particular hepatitis B through immunization. However, there is a substantial burden of people chronically infected with hepatitis B and C who have little access to treatment. In particular, new hepatitis C direct-acting antivirals (DAAs) remain expensive and are a barrier to access to treatment for all who need it.
The Informal Consultation on Access to Hepatitis Medicines in Upper-Middle- and High-Income Countries was held at the WHO Regional Office for the Western Pacific in Manila, Philippines from 21 to 22 August 2017. Presentations and discussions on regional and global approaches to dealing with intellectual property rights, financing, drug pricing, health technology assessment, and research and development of treatments for hepatitis were part of the agenda.
Participants agreed on ways forward, including consideration of joint negotiation for medicines in the Region, greater sharing of pricing information and negotiation strategies, monitoring of real world efficacy of new direct-acting antivirals, capacity-building, and platforms for information sharing.